Skip to main content
Premium Trial:

Request an Annual Quote

Lineagen Incorporating Affymetrix's GeneChip Technology into Genetic Evaluation Service

NEW YORK (GenomeWeb News) – Lineagen will incorporate Affymetrix's GeneChip technology into its genetic evaluation service for patients with developmental delay, intellectual disability, and autism spectrum disorders, under a deal announced today.

The agreement gives Lineagen exclusive rights to develop a chromosomal microarray assay based on the GeneChip technology platform as part of the Powered by Affymetrix program. Lineagen's service, called FirstStepDx, will feature a proprietary microarray-based assay with novel genetic markers from recent studies of more than 10,000 individuals.

The service is anticipated to become available in the middle of this year.

"This next-generation FirstStepDx will assist physicians in the diagnostic evaluation of individuals with DD, ID, or ASD to determine genetic etiology that may influence changes in clinical management and inform appropriate care," Lineagen President and CEO Michael Paul said in a statement. "The Powered by Affymetrix program will further ensure we can continue to advance our breakthrough genetic testing by providing market-leading, reproducible, and accurate results."

Financial and other terms were not disclosed.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.